AR058841A1 - Estructura polimerica semejante a dendrimero para la obtencion de conjugados de interes farmaceutico - Google Patents

Estructura polimerica semejante a dendrimero para la obtencion de conjugados de interes farmaceutico

Info

Publication number
AR058841A1
AR058841A1 ARP060105233A ARP060105233A AR058841A1 AR 058841 A1 AR058841 A1 AR 058841A1 AR P060105233 A ARP060105233 A AR P060105233A AR P060105233 A ARP060105233 A AR P060105233A AR 058841 A1 AR058841 A1 AR 058841A1
Authority
AR
Argentina
Prior art keywords
structure similar
dendrimero
pharmaceutical interest
polymer structure
obtain conjugates
Prior art date
Application number
ARP060105233A
Other languages
English (en)
Inventor
Odio Fidel Raul Castro
Martinez Vivian Maria Saez
Hernandez Jose Angel Ramon
Sanchez Eduardo Fernandez
Meireles Rolando Paez
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Publication of AR058841A1 publication Critical patent/AR058841A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/26—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/321—Polymers modified by chemical after-treatment with inorganic compounds
    • C08G65/325—Polymers modified by chemical after-treatment with inorganic compounds containing nitrogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polyethers (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)

Abstract

Una estructura polimérica semejante a dendrímero con cuatro ramas de monometoxipolietilénglicol, que puede ser representada como: (1). El grupo carboxílico de la estructura anterior puede ser funcionalizado para la obtencion de conjugados de interés farmacéutico. La union de este polietilénglicol semejante a dendrímeros a proteínas terapéuticas mejora la estabilidad in vitro e in vivo de éstas.
ARP060105233A 2005-11-30 2006-11-28 Estructura polimerica semejante a dendrimero para la obtencion de conjugados de interes farmaceutico AR058841A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20050241A CU23556A1 (es) 2005-11-30 2005-11-30 Estructura polimérica semejante a dendrímero para la obtención de conjugados de interés farmacéutico

Publications (1)

Publication Number Publication Date
AR058841A1 true AR058841A1 (es) 2008-02-27

Family

ID=37672068

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060105233A AR058841A1 (es) 2005-11-30 2006-11-28 Estructura polimerica semejante a dendrimero para la obtencion de conjugados de interes farmaceutico

Country Status (17)

Country Link
US (1) US8703893B2 (es)
EP (1) EP1967212B1 (es)
JP (1) JP5123201B2 (es)
KR (1) KR101134983B1 (es)
CN (2) CN101389354A (es)
AR (1) AR058841A1 (es)
AU (1) AU2006319636B2 (es)
BR (1) BRPI0604313A (es)
CA (1) CA2631335C (es)
CU (1) CU23556A1 (es)
EG (1) EG26619A (es)
MY (1) MY150739A (es)
RU (1) RU2409389C2 (es)
UA (1) UA91575C2 (es)
UY (1) UY29981A1 (es)
WO (1) WO2007062610A2 (es)
ZA (1) ZA200804694B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006336176B2 (en) * 2006-01-20 2013-08-22 Starpharma Pty Limited Modified macromolecule
WO2009151687A2 (en) 2008-03-12 2009-12-17 The Regents Of The University Of Michigan Dendrimer conjugates
US8889635B2 (en) * 2008-09-30 2014-11-18 The Regents Of The University Of Michigan Dendrimer conjugates
WO2010054321A2 (en) 2008-11-07 2010-05-14 The Regents Of The University Of Michigan Methods of treating autoimmune disorders and/or inflammatory disorders
US20100158850A1 (en) * 2008-12-23 2010-06-24 The Regents Of The University Of Michigan Dendrimer based modular platforms
EP2488172A4 (en) * 2009-10-13 2014-08-13 Univ Michigan DENDRIMER COMPOSITION AND METHOD FOR THEIR SYNTHESIS
US8912323B2 (en) 2009-10-30 2014-12-16 The Regents Of The University Of Michigan Multifunctional small molecules
US9402911B2 (en) 2011-12-08 2016-08-02 The Regents Of The University Of Michigan Multifunctional small molecules
EP2793953B1 (en) * 2011-12-21 2019-12-04 The Regents of The University of California Telodendrimers with enhanced drug delivery
US9642916B2 (en) 2012-12-12 2017-05-09 The Regents Of The University Of California Porphyrin modified telodendrimers
NZ712948A (en) * 2013-03-05 2021-01-29 Hanmi Pharm Ind Co Ltd Improved preparation method for high-yield production of physiologically active polypeptide conjugate
EP2786766A1 (en) * 2013-04-05 2014-10-08 Ufpeptides S.r.l. Supramolecular aggregates comprising maleimido cores
WO2014207769A1 (en) 2013-06-27 2014-12-31 Mylan Laboratories Ltd Process for the preparation of nepafenac
CU20140003A7 (es) * 2014-01-08 2015-08-27 Ct De Inmunología Molecular Biofarmacuba Conjugado que comprende eritropoyetina y una estructura polimérica ramificada
LT3183264T (lt) 2014-08-19 2021-01-11 Biogen Ma Inc. Pegilinimo būdas
KR20180017104A (ko) * 2015-06-11 2018-02-20 앰비오 파마슈티컬스, 엘엘씨 Peg화된 과립세포 콜로니 자극 인자(gcsf)
US11013756B2 (en) 2015-12-04 2021-05-25 Zenyaku Kogyo Co., Ltd. Anti-IL-17 aptamer having improved retention in blood
EP3400020A1 (en) 2016-01-08 2018-11-14 Ascendis Pharma Growth Disorders A/S Cnp prodrugs with large carrier moieties
CA3008017C (en) 2016-01-08 2024-01-02 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with reduced side-effects
NZ743488A (en) 2016-01-08 2023-02-24 Ascendis Pharma Growth Disorders As Controlled-release cnp agonists with low initial npr-b activity
HUE060521T2 (hu) 2016-01-08 2023-03-28 Ascendis Pharma Growth Disorders As A gyûrûn hordozó gyököt tartalmazó CNP elõvegyületek
SG11201805028RA (en) 2016-01-08 2018-07-30 Ascendis Pharma Growth Disorders As Controlled-release cnp agonists with increased nep stability
NZ743489A (en) 2016-01-08 2022-09-30 Ascendis Pharma Growth Disorders As Controlled-release cnp agonists with low npr-c binding
EP3512569A4 (en) 2016-09-15 2020-09-23 The Regents of The University of California ENHANCED HYBRID TELODENDRIMERS
AU2017336253B2 (en) 2016-09-29 2023-02-23 Ascendis Pharma Growth Disorders A/S Combination therapy with controlled-release CNP agonists
WO2019001473A1 (zh) * 2017-06-28 2019-01-03 北京键凯科技股份有限公司 一种树状多缩乙二醇衍生物及其制备方法和应用
CN109134282B (zh) * 2017-06-28 2021-03-16 北京键凯科技股份有限公司 一种树状多缩乙二醇衍生物及其制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4732863A (en) 1984-12-31 1988-03-22 University Of New Mexico PEG-modified antibody with reduced affinity for cell surface Fc receptors
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5985263A (en) * 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
DE60137525D1 (de) * 2000-10-16 2009-03-12 Chugai Pharmaceutical Co Ltd Peg-modifiziertes erythropoietin
US7026440B2 (en) * 2001-11-07 2006-04-11 Nektar Therapeutics Al, Corporation Branched polymers and their conjugates
CN1569892A (zh) * 2004-04-30 2005-01-26 新峰生物科技（上海）有限公司 多臂树杈型聚乙二醇与蛋白质或多肽的结合物及其制备方法
US7144978B2 (en) * 2002-01-15 2006-12-05 Pan Asia Bio Co., Ltd. Multidrop tree branching functional polyethylene glycol, methods of preparing and using same
CN1176137C (zh) * 2002-01-15 2004-11-17 泛亚生物技术有限公司 多臂树杈型功能化聚乙二醇制备方法及它在药物中的应用
ITMI20020951A1 (it) * 2002-05-06 2003-11-06 Univ Degli Studi Trieste Derivati multifunzionali del polietilenglicole loro preparazione ed impiego
AU2004251602B2 (en) * 2003-05-23 2010-05-13 Nektar Therapeutics PEG derivatives having an amidocarbonate linkage
JP2007501812A (ja) * 2003-08-08 2007-02-01 ノボ　ノルディスク　アクティーゼルスカブ ペプチドのための結合剤として新しい構造上十分に定義された枝分れしたポリマーの合成および適用
CA2552892C (en) * 2004-01-08 2014-08-05 Neose Technologies, Inc. O-linked glycosylation of peptides
US20060036080A1 (en) * 2004-07-16 2006-02-16 Bossard Mary J Conjugates of GM-CSF moiety and a polymer
KR20070108180A (ko) * 2005-02-16 2007-11-08 노보 노르디스크 에이/에스 구조적으로 잘 정의된 분지형 중합체와 콘쥬게이트된인슐린분비제 유도체
US7714114B2 (en) * 2005-02-16 2010-05-11 Nektar Therapeutics Conjugates of an EPO moiety and a polymer

Also Published As

Publication number Publication date
US20090082537A1 (en) 2009-03-26
EG26619A (en) 2014-04-08
CA2631335C (en) 2013-07-16
BRPI0604313A (pt) 2007-01-30
EP1967212A2 (en) 2008-09-10
CN101389354A (zh) 2009-03-18
JP2009517414A (ja) 2009-04-30
EP1967212B1 (en) 2016-09-21
RU2409389C2 (ru) 2011-01-20
WO2007062610A2 (es) 2007-06-07
UA91575C2 (ru) 2010-08-10
MY150739A (en) 2014-02-28
CA2631335A1 (en) 2007-06-07
RU2008126209A (ru) 2010-01-10
AU2006319636A1 (en) 2007-06-07
CU23556A1 (es) 2010-07-20
KR101134983B1 (ko) 2012-04-09
UY29981A1 (es) 2007-06-29
CN104906594A (zh) 2015-09-16
ZA200804694B (en) 2009-03-25
JP5123201B2 (ja) 2013-01-23
AU2006319636B2 (en) 2012-10-18
WO2007062610A3 (es) 2007-09-20
US8703893B2 (en) 2014-04-22
KR20080072960A (ko) 2008-08-07
CN104906594B (zh) 2016-12-28

Similar Documents

Publication Publication Date Title
AR058841A1 (es) Estructura polimerica semejante a dendrimero para la obtencion de conjugados de interes farmaceutico
MX2020006187A (es) Conjugados polimericos del factor viii.
WO2006108052A3 (en) Peg and polysialic lysosomal enzyme conjugates via acid labile linkers for therapeutic targeting
CY1115354T1 (el) Ενωσεις πεγκυλιωμενης ινσουλινης lispro
WO2008054466A3 (en) Delivery of biologically active materials using core-shell tecto (dendritic polymers)
EA201070657A1 (ru) Биосовместимые и биоразлагаемые конъюгаты аналогов фумагиллина
CY1119954T1 (el) Ολιγοσακχαριτες που περιλαμβανουν μια ομαδα αμινοοξυ- και συζευγματα αυτων
BR112012013664A2 (pt) rabdovírus oncolítico
WO2009016433A3 (en) Oncolytic rhabdovirus
IT1396918B1 (it) Procedimento per la preparazione di nanopiastrine grafeniche ad elevata disperdibilita' in matrici polimeriche a bassa polarita' e relative composizioni polimeriche
WO2011015634A3 (en) Controlled release formulations of lipocalin muteins
ES2552651T3 (es) Composición inyectable de polidesoxirribonucleótido para el tratamiento de enfermedades osteoarticulares
MX2011009808A (es) Agentes de elaboracion de imagen optica.
MX2009011247A (es) Nanoparticulas que comprenden una ciclodextrina y una molecula biologicamente activa y sus aplicaciones.
WO2007069068A3 (en) Cell penetrating peptide conjugates for delivering nucleic acids into cells
WO2012116272A3 (en) Polymer conjugated protein micelles
WO2010033220A3 (en) Modified therapeutics peptides, methods of their preparation and use
EP2537533A3 (en) Antitumoral bioconjugates of hyaluronic acid or its derivatives obtained by indirect chemical conjugation
MY160922A (en) Polyethylene glycol conjugated blood coagulation factor vii
NZ592688A (en) Modified blood factors comprising a low degree of water soluble polymer
CO6280503A2 (es) Conjugados de neurturina novedosas para uso farmaceutico
WO2009121997A3 (es) Nanopartículas pegiladas que comprenden una molécula biológicamente activa y sus aplicaciones
WO2009030065A8 (zh) 聚乙二醇修饰的干扰素α2a及其制备方法和应用
BR112015022730A2 (pt) formulações de rfviii, método para conjugação covalente de rfviii com um polímero biocompatível e uso de rfviii no preparo de formulação de rfviii para tratamento de hemofilia a
ATE449125T1 (de) Mittels wasserabweisender gruppen funktionalisierte verzweigte polyaminosäuren und deren verwendung, insbesondere für therapeutische zwecke

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed, e.g., due to non-payment of fee